Mode
Text Size
Log in / Sign up
N/A N=150

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

Fallopian Tube Cancer · Ovarian Cancer · Ovarian Neoplasms · Ovary Cancer · Fallopian Tube Neoplasms

Enrolled (actual)
150
Serious AEs
2.3%
Results posted
Jan 2021
Primary outcome: Primary: Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement — .143; .959 Proportion of Cytuity Cell Samples

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Hysteroscopic cell sampling of the fallopian tube (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Boston Scientific Corporation
Primary completion
Feb 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement
.143; .959
SECONDARY
PPV, NPV and Diagnostic Accuracy for Fallopian Tube Involvement
0.221; 0.932; .894
SECONDARY
Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Fallopian Tube
.077; .952; .108; .932; .888
SECONDARY
Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy of the Ovaries
.091; .963; .281; .883; .851
SECONDARY
Sensitivity, Specificity, PPV, NPV and Diagnostic Accuracy for Subject Level Analysis
2; 58; 2; 58; 60

Summary

Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.

Eligibility Criteria

Inclusion Criteria

  • Subject is medically cleared for surgery
  • Subject is scheduled to undergo salpingo-oophorectomy or salpingectomy for a pelvic mass suspicious for malignancy
  • Subject must be 18 years of age
  • Subject must be able to provide informed consent

Exclusion Criteria

  • Contraindication to hysteroscopy
  • Acute pelvic inflammatory disease
  • Active or recent lower pelvic infection
  • Pregnancy
  • Delivery or termination of a pregnancy in the past 6 weeks
  • Known tubal obstruction
  • Tubal ligation
  • Invasive carcinoma of the cervix or endometrium
  • Intolerance of anesthesia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03593681). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search